FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:							

to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b).

1. Name and Address of Reporting Person* <u>Brown Ryan Edward</u>						2. Issuer Name and Ticker or Trading Symbol Sarepta Therapeutics, Inc. [ SRPT ]									tionship of Reporting all applicable)  Director		ng Person(s) to Is 10% Ov Other (s		wner	
(Last) 215 FIRS	(Last) (First) (Middle) 215 FIRST STREET					3. Date of Earliest Transaction (Month/Day/Year) 03/01/2023								X	Officer (give title below)  SVP, Gene		below) eral Counsel		specify	
(Street) CAMBR (City)			)2124 Zip)		4. If <i>I</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								. Indivine)	Form Form	al or Joint/Group Filing (Check Applicable form filed by One Reporting Person form filed by More than One Reporting Person				
		Table	1 - No	n-Deriva	tive S	Secu	rities	Acc	uired	, Dis	posed of	, or B	enefic	ially	Own	ed				
1. Title of Security (Instr. 3) 2. Trans Date			2. Transact	tion 2A. D Execu		2A. Deemed Execution Date, if any (Month/Day/Year)		3. 4. Securities Disposed Of Code (Instr. 8)		S Acquir	ed (A) or	or 5. Amo 4 and Securi Benefi Owned		ount of ties cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price			ction(s) 3 and 4)			(Instr. 4)	
Common Stock			03/01/2	2023				F		196(1)	D	\$147	47.57 2		25,645		D			
		Та	ble II								osed of, convertib			-	Owne	d				
1. Title of Derivative Security (Instr. 3)			Code (	ansaction of ode (Instr. Derivative			6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)  Amount or Number of Title Shares		nt er		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

## **Explanation of Responses:**

1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on 02/28/2020.

## Remarks:

/s/ Ryan E. Brown

03/03/2023

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.